Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Esophageal Neoplasm
Interventions
DRUG

cisplatin and paclitaxel

"1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."

Trial Locations (9)

100029

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

410013

Hunan Province Tumor Hospital, Changsha

450008

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou

510060

Sun Yat-sen Uniersity Cancer Center, Guangzhou

Unknown

Fujian Medical University Union Hospital, Fuzhou

Anyang cancer hospital, Anyang

Fudan Universitay Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Hunan Province Tumor Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Henan Cancer Hospital

OTHER_GOV

NCT02395705 - Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter